MX2023012325A - Anticuerpos anti-tslp modificados. - Google Patents

Anticuerpos anti-tslp modificados.

Info

Publication number
MX2023012325A
MX2023012325A MX2023012325A MX2023012325A MX2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A
Authority
MX
Mexico
Prior art keywords
modified anti
tslp antibodies
tezepelumab
tslp
antibodies
Prior art date
Application number
MX2023012325A
Other languages
English (en)
Inventor
Pavel Bondarenko
Hao Zhang
Liuqing Shi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023012325A publication Critical patent/MX2023012325A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud se refiere, en general, a composiciones o variantes del anticuerpo anti-TSLP tezepelumab que tienen una estabilidad aumentada en comparación con el tezepelumab cuando se almacena durante largos períodos de tiempo.
MX2023012325A 2021-04-23 2022-04-22 Anticuerpos anti-tslp modificados. MX2023012325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178915P 2021-04-23 2021-04-23
PCT/US2022/025999 WO2022226342A2 (en) 2021-04-23 2022-04-22 Modified anti-tslp antibodies

Publications (1)

Publication Number Publication Date
MX2023012325A true MX2023012325A (es) 2023-10-30

Family

ID=81597885

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012325A MX2023012325A (es) 2021-04-23 2022-04-22 Anticuerpos anti-tslp modificados.

Country Status (14)

Country Link
US (1) US20240182558A1 (es)
EP (1) EP4326762A2 (es)
JP (1) JP2024516595A (es)
KR (1) KR20230175245A (es)
CN (1) CN117177992A (es)
AR (1) AR125404A1 (es)
AU (1) AU2022262006A1 (es)
BR (1) BR112023022041A2 (es)
CA (1) CA3216700A1 (es)
CL (1) CL2023003124A1 (es)
IL (1) IL307439A (es)
MX (1) MX2023012325A (es)
TW (1) TW202304980A (es)
WO (1) WO2022226342A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024118542A1 (en) * 2022-11-28 2024-06-06 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions
WO2024146630A1 (zh) * 2023-01-06 2024-07-11 江苏恒瑞医药股份有限公司 一种tslp抗体治疗哮喘的方法
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
JP4986633B2 (ja) * 2005-01-12 2012-07-25 協和発酵キリン株式会社 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
SI2202245T1 (sl) * 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
TW201201840A (en) 2010-07-15 2012-01-16 Hoffmann La Roche Antibodies specifically binding to human TSLPR and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
TW201643179A (zh) * 2015-03-11 2016-12-16 葛蘭素史克智慧財產發展有限公司 Ｔｓｌｐ結合蛋白
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
KR102560646B1 (ko) * 2017-08-01 2023-07-27 암젠 인크 질량 분광분석법으로의 분석을 위한 폴리펩티드 샘플의 실시간 제조를 위한 시스템 및 방법
US11191904B2 (en) 2017-11-10 2021-12-07 Amgen Inc. Plungers for drug delivery devices
CA3093699A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
US12053617B2 (en) 2018-10-15 2024-08-06 Amgen Inc. Drug delivery device having damping mechanism
JP2022504805A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド 薬物送達デバイスのプラットフォーム式組み立てプロセス
EP3980786A1 (en) 2019-06-05 2022-04-13 Amgen Inc. Methods of identifying attributes of therapeutic proteins

Also Published As

Publication number Publication date
CA3216700A1 (en) 2022-10-27
CL2023003124A1 (es) 2024-04-26
AR125404A1 (es) 2023-07-12
AU2022262006A1 (en) 2023-10-19
KR20230175245A (ko) 2023-12-29
JP2024516595A (ja) 2024-04-16
IL307439A (en) 2023-12-01
WO2022226342A2 (en) 2022-10-27
US20240182558A1 (en) 2024-06-06
BR112023022041A2 (pt) 2023-12-26
EP4326762A2 (en) 2024-02-28
TW202304980A (zh) 2023-02-01
WO2022226342A3 (en) 2022-12-01
CN117177992A (zh) 2023-12-05

Similar Documents

Publication Publication Date Title
MX2023012325A (es) Anticuerpos anti-tslp modificados.
MX2018002999A (es) Composiciones de inoculante estables y metodos para producir las mismas.
UA112416C2 (uk) Антитіло до fap і способи його застосування
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
MX2015012562A (es) Purificacion de conjugados anticuerpo-farmaco (cafs).
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
EA200601894A1 (ru) Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
MX2022010621A (es) Anticuerpos anti-cd19 humano.
EP4223786A3 (en) Novel anti-pad4 antibodies
EA201390467A1 (ru) Композиции антител и способы применения
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
MX2021011995A (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2023011561A (es) Anticuerpos anti-nectina-4 y usos de los mismos.
WO2021076574A3 (en) Fn3 domain-sirna conjugates and uses thereof
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
MX2019009759A (es) Composiciones de peptido estables.
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
CR20230531A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
MX2024001644A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana.